<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04969406</url>
  </required_header>
  <id_info>
    <org_study_id>P21-02</org_study_id>
    <nct_id>NCT04969406</nct_id>
  </id_info>
  <brief_title>A Prospective Trial of the Intelon BOSS(TM) System</brief_title>
  <official_title>A Prospective Trial Designed to Evaluate the Repeatability and Reproducibility of the Intelon BOSS(TM) System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intelon Optics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intelon Optics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open-label, single-site clinical trial designed to evaluate the repeatability&#xD;
      and reproducibility of biomechanical imaging by the BOSS device. Subjects will undergo&#xD;
      unilateral biomechanical mapping of the cornea and lens by three BOSS devices operated by&#xD;
      three (3) different operators.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of variance in corneal and lens measurements to determine repeatability and reproducibility</measure>
    <time_frame>Evaluation Visit (within 30 days of the Screening Visit)</time_frame>
    <description>A random effect model will be used to assess variation due to device/operator configuration</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cornea</condition>
  <condition>Lens Diseases</condition>
  <arm_group>
    <arm_group_label>Imaging by BOSS System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imaging by the BOSS System</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brillouin Spectroscopy via BOSS System</intervention_name>
    <description>Biomechanical Imaging of the Cornea and Lens</description>
    <arm_group_label>Imaging by BOSS System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older&#xD;
&#xD;
          2. Availability, willingness and sufficient cognitive awareness to comply with the&#xD;
             examination procedures and schedule&#xD;
&#xD;
          3. Signed Written Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No light perception or low vision rendering the subject unable to fixate to keep gaze&#xD;
             still enough to acquire images&#xD;
&#xD;
          2. Presence of corneal opacity&#xD;
&#xD;
          3. Presence of cortical cataracts visible in an undilated pupil&#xD;
&#xD;
          4. Any systemic disease or disorder which would prohibit image acquisition (e.g.,&#xD;
             Parkinson's Disease).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Claire Barnes, PhD</last_name>
    <phone>(650) 690-0308</phone>
    <email>cbarnes@intelon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vold Vision plc</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lens Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

